Global Antiemetic Drug Market 2017-2021
About Antiemetic Drug
Emesis is defined as forceful expulsion of stomach content either due to humoral stimulation due to chemoreceptor trigger zone (CRTZ) or neural stimulation of emetic centers. The various drugs that are used to treat this condition of emesis are known as antiemetics. The various classes of drug available for management of emesis are serotonin antagonist, dopamine antagonist, NK1 receptor antagonist, antihistaminic, steroids, and anticholinergic. The various applications of antiemetic drugs include chemotherapy, surgery, gastroenteritis, morning sickness, motion sickness, stress-induced emesis, and drugs-induced emesis. This market is primarily volume driven as majority of drugs are available in generic form.
Technavio’s analysts forecast the global antiemetic drug market to grow at a CAGR of 6.13% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global antiemetic drug market for 2017-2021. To calculate the market size, the report considers the sales from branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Antiemetic Drug Market 2017-2021
Technavio recognizes the following companies as the key players in the global antiemetic drug market: GlaxoSmithKline, Johnson & Johnson, Pfizer, and Sanofi.
Other Prominent Vendors in the market are: bbott, Bristol-Myers Squibb, Cipla, Eisai, Eli Lilly, Glenmark, Helsinn Healthcare, Heron Therapeutics, IPCA Laboratories, Lupin, Merck, Novartis, RedHill, Sun Pharmaceutical Industries, and Takeda Pharmaceutical.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is inorganic growth strategies. The inorganic growth strategies are expected to contribute the growth of antiemetic drug market. These inorganic growth strategies include global M&A, partnerships, and regional acquisition. Owing to these inorganic growth strategies, the market penetration of vendors is improved, technological advancement due to mutual collaboration in R&D, and improved the product portfolio.”
According to the report, one of the major drivers for this market is increased prevalence of cancer. With this ever-increasing population of cancer patients, effective therapies are necessary to save lives and improve their quality of life. Chemotherapy is widely used therapy to help individuals fight cancer. The data estimated that around 3.8-4.2 million cancer patients undergo chemotherapy treatment every year. However, chemotherapy is associated with many side effects. The majority of chemotherapeutic agents cause serious nausea and vomiting with its treatment. This is termed as CINV. The data also reported that around eight out 10 patients undergoing chemotherapy encounter CINV as a debilitating side effect. It is one of the major factors for premature discontinuation of chemotherapy.
Further, the report states that one of the major factors hindering the growth of this market is lack of animal models. Nausea and vomiting are most common symptoms associated either as a symptom of a disease or the side effect of a various class of drugs. The development of newer antiemetic drugs and analyzing emetic liability in novel chemical entities mainly rely on the models that mimic the complexity of these multi-system reflexes. Animal models in preclinical studies are widely used for examining the safety, efficacy, and toxicity of molecule under examination before evaluating it on human volunteers.
GlaxoSmithKline, Johnson & Johnson, Pfizer, Sanofi, bbott, Bristol-Myers Squibb, Cipla, Eisai, Eli Lilly, Glenmark, Helsinn Healthcare, Heron Therapeutics, IPCA Laboratories, Lupin, Merck, Novartis, RedHill, Sun Pharmaceutical Industries, and Takeda Pharmaceutical.